Catalyst
Slingshot members are tracking this event:
JNJ subsidiary Janssen files FDA application for approval of Guselkumab for treating moderate to severe plaque psoriasis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| JNJ | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 25, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda Application, Guselkumab, Plaque Psoriasis
